Breakthrough in Understanding Late Breast Cancer Relapse

Researchers at the Garvan Institute of Medical Research in Sydney have made a pivotal discovery that sheds light on why estrogen receptor-positive (ER+) breast cancer, the most common subtype accounting for about 70 percent of cases, can return years or even decades after successful initial treatment. This finding challenges long-held assumptions about cancer dormancy and opens new avenues for preventing metastatic spread.

The study reveals that certain breast cancer cells adopt a strategy of extreme slow growth rather than complete quiescence during hormone therapy. These slow-cycling cells persist, migrate to distant sites like the bone and lungs, and form tiny secondary tumors known as micrometastases. Over time, these specks can expand into life-threatening malignancies, explaining the persistent risk of late relapse observed in up to 30 percent of ER+ patients.

Led by Associate Professor Liz Caldon and first author Kristine Fernandez, the team spent years isolating these elusive cells, demonstrating their metastatic potential in preclinical models. Their work highlights the P-Rex1/Rac1 signaling pathway as a key driver, suggesting targeted inhibitors could disrupt this covert survival mechanism.

Estrogen Receptor-Positive Breast Cancer: The Dominant Subtype

Estrogen receptor-positive (ER+) breast cancer develops when cancer cells have receptors that bind to the hormone estrogen, fueling uncontrolled growth. This subtype represents the majority of diagnoses worldwide, with over 2.3 million new cases annually according to global health data. Standard treatment involves surgery, radiation, chemotherapy, and extended endocrine therapy—drugs like tamoxifen or aromatase inhibitors that block estrogen signaling—for five to ten years.

While initial response rates exceed 90 percent, late recurrences remain a challenge. Studies show a steady annual risk of about 1 percent for distant metastasis even 20 years post-diagnosis. In Australia alone, breast cancer claims over 3,300 lives yearly, many from these delayed returns.

The Garvan team's insight explains this phenomenon: therapy doesn't eliminate all cells but reprograms a subset to slow their division cycle, evading detection and destruction.

The Hidden World of Slow-Cycling Cancer Cells

Traditional models posited that residual cancer cells enter full dormancy—a reversible arrest—lying inactive until external signals awaken them. However, Caldon's group identified an alternative: cells that never fully halt but divide at a glacial pace, perhaps once every few weeks or months.

These slow-cycling cells emerge rapidly upon endocrine therapy initiation. Using advanced cell sorting and long-term cultures, researchers isolated them from patient-derived models. Despite minimal proliferation, they displayed heightened motility, invading matrices and disseminating to metastatic niches.

In mouse models, injected slow-cycling cells formed micrometastases in bone and lung, sites responsible for 70 percent of breast cancer deaths. This 'slow clock' strategy allows persistence under therapy pressure, where fast-dividing cells perish.

Unraveling the P-Rex1/Rac1 Signaling Pathway

At the molecular heart is the P-Rex1/Rac1 pathway, a guanine exchange factor system regulating cell migration, cytoskeletal dynamics, and survival. In slow-cycling cells, endocrine therapy upregulates P-Rex1, activating Rac1 to promote pseudopod formation and extracellular matrix degradation.

Live-cell biosensor imaging confirmed Rac1 hyperactivation specifically in these cells. Pharmacological or genetic blockade shrank tumors and curbed metastasis in xenografts, validating the pathway's necessity.

This mechanism parallels adaptive responses in other cancers but is uniquely tied to hormone deprivation here. For full details, explore the original research in Nature Communications.

Experimental Approaches: From Bench to Preclinical Insight

Isolating slow-cycling cells required patience: standard cultures favor fast growers, so the team used low-density plating and fluorescent timers tracking division history. Over years, they enriched for cells with extended cycles.

Patient-derived xenografts (PDXs) from therapy-naive ER+ tumors mimicked clinical responses. Post-treatment, slow-cycling fractions dominated residuals. Orthotopic injections traced dissemination, with biosensors revealing real-time Rac1 dynamics.

These rigorous methods bridge lab observations to human relevance, setting a gold standard for dormancy research.

Photo by Matthew Stephenson on Unsplash

Implications for Clinical Practice and Patient Outcomes

For the 30 percent at relapse risk, this suggests adjunct therapies: Rac1 inhibitors, already in trials for other indications, could pair with endocrine agents. Biomarkers tracking slow-cycling signatures might personalize therapy duration, sparing low-risk patients prolonged exposure.

Monitoring micrometastases via liquid biopsies or imaging could detect 'pebbles' early. In Australia, where Garvan's work resonates, national screening programs may integrate these advances.

Professor Caldon notes, "A slow clock doesn't mean a stopped clock—these cells migrate and seed relapse undetected." Early intervention could transform survival curves.

Garvan Institute and UNSW Sydney: Hubs of Cancer Innovation

The Garvan Institute, nestled in Sydney's medical precinct, pioneers genomics-driven discovery. Affiliated with the University of New South Wales (UNSW Sydney), it trains PhD students and postdocs in cutting-edge oncology.

Caldon's lab exemplifies this: Fernandez, a senior research assistant, credits multidisciplinary training. UNSW's strengths in bioinformatics and preclinical modeling bolster such efforts, producing high-impact papers annually.

This study underscores Australia's research prowess, with National Breast Cancer Foundation funding accelerating translation.

Broader Context: Dormancy Research Landscape

Global efforts complement Garvan's: Penn Medicine trials target dormant cells with bisphosphonates, achieving clearance in 80 percent. European groups probe IL-1β awakening signals.

Yet, slow-cycling adds nuance—heterogeneity demands multi-pronged attacks. Collaborations like NBCF's AllClear program, involving Garvan, aim to halve deaths via dormancy eradication.

Read more on related advances via News-Medical.

Career Pathways in Oncology Research

This discovery highlights vibrant opportunities for higher education graduates. PhD programs at UNSW/Garvan focus on cancer plasticity, offering stipends, international networks, and publication tracks.

• Postdoctoral fellowships in metastasis biology
• Research assistant roles in preclinical modeling
• Lecturer positions teaching tumor microenvironment
• Industry transitions to biotech firms developing Rac1 drugs

With demand surging—global oncology workforce shortages projected at 4 million by 2030—skills in single-cell sequencing and PDX are prized.

Global Statistics and Societal Impact

Worldwide, breast cancer recurs in 20-30 percent of early-stage cases, with ER+ late events comprising half. In high-income nations, 5-year survival nears 90 percent, but 20-year distant recurrence risks persist at 10-20 percent.

Australia's incidence rate—1 in 7 women lifetime risk—mirrors this, fueling investments like $25 million AllClear grants. Equity gaps persist: Indigenous rates 1.3 times higher.

Innovations like Garvan's promise equitable gains, reducing psychological relapse burden.

Photo by Matthew Stephenson on Unsplash

Future Directions and Ongoing Challenges

Next: clinical trials combining Rac1 inhibitors with CDK4/6 blockers; AI-driven slow-cycling predictors; bone marrow sampling for minimal residual disease.

Challenges include off-target effects, resistance evolution, and trial recruitment. Yet, optimism prevails—personalized oncology evolves rapidly.

Caldon envisions, "Better tracking of hormone therapy efficacy over a decade, preventing recurrence for those under constant threat."

Stakeholder Perspectives and Actionable Insights

Patients advocate extended surveillance; clinicians eye combo regimens; researchers call for data-sharing consortia.

• Step 1: Genomic profiling at diagnosis for dormancy risk
• Step 2: Serial ctDNA monitoring post-therapy
• Step 3: Trial enrollment for high-risk profiles

This holistic view empowers academia, healthcare, and survivors alike.